Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”)
List of Group Companies(As of March 31, 2022)
Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)

Relationship

Note(Consolidated Subsidiaries)
Unit=million
KAN ResearchInstitute, Inc.

Kobe, Japan

70

JPY

Pharmaceutical R&D

100.00%Eisai Distribution
Co., Ltd.

Kanagawa, Japan

60

JPY

Pharmaceuticallogistics

100.00%Eisai R&D
Management Co.,Ltd.

Tokyo, Japan

16

JPY

Management ofpharmaceutical R&D

100.00%Sunplanet Co.,Ltd.

Tokyo, Japan

455

JPY

Business support
services, etc.

85.07%EA Pharma Co.,Ltd.

Tokyo, Japan

9,145

JPY

Pharmaceutical R&D/ production / sales

60.00%

Arteryex Inc.

Tokyo, Japan434

JPY

Software planningand development

64.42%

Eisai Corporationof North America

New Jersey,
USA2,266,700

Americas holding
company

100.00%Eisai Inc.

New Jersey,
USA

151,600

USD

Pharmaceutical R&D/ production / sales

100.00%(100.00%)

H3 Biomedicine
Inc.

Massachusetts, USA

8USD

Pharmaceutical R&D

100.00%(100.00%)

Eisai Innovation,
Inc.

Massachusetts, USA

1USD

Management ofpharmaceuticalinvestment

100.00%(100.00%)

Eisai Ltd.

Ontario, Canada

30,000CAD

Eisai China
Holdings Ltd.

Jiangsu, China

664,465

RMB

Pharmaceutical sales
Chineseheadquarters /holding company

100.00%(100.00%)
100.00%(100.00%)

Eisai China Inc.

Jiangsu, China

576,125

RMB

Pharmaceuticalproduction / sales

Eisai (Suzhou)
Trading Co., Ltd.

Jiangsu, China

70,000

RMB

Eisai (Liaoning)
PharmaceuticalCo., Ltd.

Liaoning, China

50,000Eisai Europe Ltd.

Hertfordshire,
UK

Eisai Ltd.

The Company
commissions
pharmaceutical R&D
The Company
commissions
pharmaceutical logistics
The Company
commissions a part ofmanagement and otherfunctions related to R&D
The Company purchasesbusiness support services,etc.
The Company
commissions
pharmaceutical R&D andproduction / purchases
pharmaceutical products

*3-

*7-

*3

Unit=thousand
USD

The Company
commissions
pharmaceutical R&D andproduction / sells
pharmaceutical products
and APIThe Company
commissions
pharmaceutical R&D
The Company
commissions managementof investment in the U.S.
and Europe-

*3*5-

*3

100.00%(100.00%)

The Company sells
pharmaceutical products
and API*3

Pharmaceutical sales

100.00%(100.00%)

The Company sells
pharmaceutical products*3RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)-184,138

GBPEurope headquarters/ holding company,
pharmaceutical sales

100.00%Hertfordshire,UK

46,009GBP

Pharmaceutical R&D/ sales100.00%(100.00%)

Eisai
Manufacturing Ltd.

Hertfordshire,UK

38,807

GBP

Pharmaceutical R&D/ production

100.00%(100.00%)

Eisai GmbH

Frankfurt,
Germany

7,669

EUR

Pharmaceutical sales

Eisai S.A.S.

Paris, France

19,500EUR

Pharmaceutical sales

Eisai B.V.

Amsterdam,
Netherlands

540

EUR

Pharmaceutical sales

Eisai
Farmacéutica S.A.

Madrid, Spain

4,000

EUR

Pharmaceutical sales

Eisai S.r.l.

Milan, Italy

3,500

EUR

Pharmaceutical sales

Eisai Pharma AGZurich,
Switzerland
Stockholm,
Sweden

3,000

CHF

Pharmaceutical sales

10,000SEK

Pharmaceutical sales

100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)

Eisai ABThe Company
commissions management
and administration ofpharmaceutical business
The Company
commissions
pharmaceutical R&D
The Company sells
pharmaceutical products
and API / is commissioned
pharmaceutical R&D-*3*3*3

Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)

Relationship

Note

Unit= thousand
Eisai Farmacêutica,
Unipessoal Lda.

Lisbon,Portugal

1,250

EUR

Pharmaceutical sales

100.00%(100.00%)-

Eisai SA/NV

Brussels,
Belgium

2,001

EUR

Pharmaceutical sales

100.00%(100.00%)-Eisai GesmbH

Vienna,Austria

2,000

EUR

Pharmaceutical sales

100.00%(100.00%)-Limited Liability
Company Eisai

Moscow,
Russia

4,000

RUB

Pharmaceutical sales

100.00%(100.00%)-

Eisai Israel Ltd.

Tel Aviv,
Israel5,000ILS

Pharmaceuticalbusiness100.00%(100.00%)-Eisai Asia Regional
Services Pte. Ltd.

Singapore

34,469

SGD

Asia holding company

100.00%-Eisai (Singapore)
Pte. Ltd.
Eisai ClinicalResearchSingapore Pte. Ltd.

Singapore

300

SGD

Pharmaceutical sales

100.00%(100.00%)

The Company sells
pharmaceutical products

Singapore

10SGD

Pharmaceutical R&D

100.00%(100.00%)

The Company commissions
pharmaceutical R&D

Eisai Taiwan Inc.

Taipei,Taiwan270,000

TWD

Pharmaceutical sales

100.00%

The Company sells
pharmaceutical products

Eisai (Thailand)Marketing Co., Ltd.

Bangkok,Thailand

103,000

THB

Pharmaceutical sales

100.00%(100.00%)

PT Eisai Indonesia

1,630,000

IDR

Pharmaceuticalproduction / sales

100.00%470

MYR

Pharmaceutical sales

100.00%(5.74%)

HI-Eisai
Pharmaceutical Inc.

Jakarta,Indonesia
Petaling
Jaya,
Malaysia
Manila,Philippines

The Company sells
pharmaceutical products
The Company sells
pharmaceutical products andAPIThe Company sells
pharmaceutical products

122,000

PHP

Pharmaceutical sales

50.00%(1.45%)The Company sells
pharmaceutical products

Eisai (Hong Kong)
Co., Ltd.

Hong Kong

500

HKD

Pharmaceutical sales

100.00%(10.00%)

The Company sells
pharmaceutical products

Eisai Korea Inc.

Seoul,South Korea

3,512,000

KRW

Pharmaceutical sales

100.00%

Eisai
Pharmaceuticals
India Pvt. Ltd.

AndhraPradesh,India

2,708,324

INR

Pharmaceutical R&D /production / sales100.00%(11.08%)The Company sells
pharmaceutical products
The Company commissions
pharmaceutical R&D andproduction / sells API /purchases pharmaceuticalproducts

Eisai Australia Pty.
Ltd.

Sydney,Australia

4,000

AUD

Pharmaceutical sales

100.00%-Eisai LaboratóriosLtda.

São Paulo,
Brazil

87,899BRL

Pharmaceutical sales

100.00%(100.00%)-

Eisai Laboratorios
S. de R.L. de C.V.

Mexico City,
Mexico3MXN

Pharmaceutical sales

100.00%(100.00%)-

Eisai New Zealand
Ltd.

Auckland,
New Zealand

2,050

NZD

Pharmaceutical sales

100.00%(100.00%)-Eisai Vietnam Co.,Ltd.

Ho Chi Minh,
Viet Nam

20,781,000

VND

Pharmaceuticalbusiness100.00%------

Eisai (Malaysia)
Sdn. Bhd.

Other—2companies-

*6

*4

*3

(Associated Companies Accounted for Using the Equity Method)
Unit=million
Bracco-Eisai Co.,Ltd.

Tokyo, Japan

340

JPY

Unlimit Health
LimitedShanghai,
China

30

RMB

Notes:

Contrast media
imports / production /sales
Provision of medical
services

49.00%
49.00%(49.00%)

The Company purchases
pharmaceutical products-*1. "Description of Operations" indicates the segment applicable to the respective entity.
*2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
*3. Significant subsidiaries.
*4. HI-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control over its operation eventhough the Company's voting rights do not exceed 50%.
*5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue reported in the consolidated
financial statements for the fiscal year ended March 31, 2022. Key financial results (in Japanese yen) of Eisai Inc. are as follows:Revenue¥252,657 mil.
Operating Profit¥30,006 mil.
Profit for the year
¥25,361 mil.
Total Equity¥341,855 mil.
Total Assets¥471,433 mil.
*6. In August 2021, Eisai Europe Ltd. established Eisai Israel Ltd.
*7. In March 2022, the Company acquired shares of Arteryex Inc. and made it a consolidated subsidiary in order to strengthen and rapidly
expand its digital solution business base.